Eleuthero
Also sold as: Eleutherococcus senticosus · Siberian ginseng · Acanthopanax senticosus · Ciwujia
A root botanical marketed as an adaptogen for fatigue and resilience. Controlled human findings are less convincing than the marketing, and it is botanically distinct from Panax ginseng.
Energy Anxiety
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Anxiety: Adding eleuthero to stress-management training did not improve stress-related fatigue or impaired concentration beyond the comparator.
- Energy: The 96-person chronic-fatigue RCT was negative overall after two months; exploratory subgroup findings do not establish efficacy.
REALITY CHECK // The best fatigue RCT was negative overall, and adding eleuthero to stress-management training did not help. Positive signals largely involve small samples, biomarkers or mixed botanical products. Calling it Siberian ginseng does not transfer Panax evidence.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
UPPER LIMIT // No established EFSA or US upper limit is supplied for eleuthero. Missing human long-term and reproductive safety data are not evidence that higher doses are safe.
Summary
The main chronic-fatigue trial (n=96, two months) was negative overall. A stress-management add-on RCT was also negative, and a review did not find credible endurance benefits. Small immune-cell or temporary quality-of-life changes do not establish fewer infections or durable wellbeing.
Mechanism
Eleutherosides B/E and other constituents are proposed to modulate HPA signaling and stress-response proteins. This is a mechanistic hypothesis; rat pharmacokinetics and cell findings do not establish human absorption or symptom improvement.
Typical studied dose
The supplied extraction does not retain a reliable numeric human trial dose. Chronic-fatigue outcomes were assessed after two months, immune-cell measures after four weeks, and older-adult wellbeing at four and eight weeks. No numeric dosing recommendation can be reconstructed safely.
Upper limit
No established EFSA or US upper limit is supplied for eleuthero. Missing human long-term and reproductive safety data are not evidence that higher doses are safe.
Popular stacks with Eleuthero
Not enough stack data yet. A combination with Eleuthero appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Dried root powder Best for: Traditional use, with uncertain active content. |
Unstandardized: active content unknown | no comparable trial range | Variable eleutherosides; human comparative PK unavailable. Occasional mild stomach symptoms. |
Caution [FORM // CHECK_SPECIFICATION] No standardized marker percentage or clinical dose equivalence can be inferred. |
| Root extract labelled 0.8% eleutherosides B + E Best for: Checking declared B/E standardization. |
Extract weight · ~0.8% marker | no comparable trial range | The cited eleutheroside PK experiment is in rats, not humans. Reported as generally tolerated; stimulant-type effects remain possible. |
Caution [FORM // CHECK_SPECIFICATION] The 0.8% specification describes a label marker, not proven superior efficacy; full extract mass is the comparison basis. |
| Liquid tincture Best for: Recognizing that drop volume is not dry extract mass. |
Unstandardized: active content unknown | no comparable trial range | Solvent and extraction ratio vary; no human comparison available. Alcohol vehicle may be unsuitable. |
Caution [FORM // CHECK_SPECIFICATION] No declared ratio is retained; do not assume a root-equivalent conversion. |
Common label traps
- TRAP_01 // CURES CHRONIC FATIGUE OR BURNOUT
The 96-person RCT was negative overall and the stress-management add-on trial was null. - TRAP_02 // SIBERIAN GINSENG IS PANAX
These are different species with different constituents and clinical evidence. - TRAP_03 // IMMUNE CELLS MEAN FEWER INFECTIONS
Small lymphocyte-count changes are surrogate outcomes; prevention of infections was not demonstrated.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- ENDURANCE PERFORMANCE Limited · no benefit
The controlled-study review did not find credible improvement in endurance; hormone and lymphocyte shifts are not performance endpoints.
PMID 15902991 PMID 11798012 - OLDER-ADULT QUALITY OF LIFE Limited · benefit
Some wellbeing measures improved at four weeks but not at eight weeks in one RCT; the signal was transient.
PMID 15207399 - IMMUNE-CELL COUNTS Limited · benefit
Small four-week study found lymphocyte changes; no reduction in clinical infections was demonstrated.
PMID 2963645 - COGNITION: COMBINATION ONLY Limited · benefit
A leaf extract plus Drynaria formula improved cognition in healthy adults, but the contribution of eleuthero cannot be isolated.
PMID 31979283 - ANTIVIRAL MECHANISM No established evidence
Cell-culture antiviral activity is preclinical; human antiviral benefit is unestablished, not disproved by a negative clinical trial.
PMID 11397509
Reader questions
How much should I take for energy?
The supplied extraction does not preserve a dependable human dose. Its main fatigue trial was negative overall, so increasing the capsule count is not a supported response to no perceived effect.
Can it cause palpitations or anxiety?
Stimulant-type symptoms are reported, particularly in stacks with caffeine. Stop for significant symptoms and seek medical assessment rather than assuming this is beneficial adaptation.
Do I need to cycle it?
The dossier does not establish receptor down-regulation or a necessary cycling schedule. Long-term safety remains limited; traditional cycling advice is not proof.
Can I take it with heart medicines?
Digoxin is a particular concern because both measured levels and their interpretation may be affected. Ask the prescriber before combining, and disclose use to the laboratory.
Stack interactions
- Caution Digoxin [CAUTION // REVIEW_COMBINATION]
Measured digoxin can rise or be distorted by assay cross-reactivity. This is a monitoring problem as well as a possible interaction; combine only with the prescriber and laboratory aware.
PMID 8705908 PMID 12580002 PMID 16040294 PMID 18623124 - Caution Immunosuppressants [CAUTION // REVIEW_COMBINATION]
A small immune-cell study suggests immunomodulation; opposition to immunosuppression is a theoretical concern, not a proven clinical interaction.
PMID 2963645 - Caution Caffeine / other stimulating adaptogens [CAUTION // REVIEW_COMBINATION]
Possible additive insomnia, anxiety, tachycardia or palpitations; synergy has not been established. - Caution Drug transport substrates [CAUTION // REVIEW_COMBINATION]
Caco-2 intestinal-cell findings suggest altered drug transport; human clinical significance is unknown.
PMID 20091240
Red flags: interactions and who should avoid it
Interactions
Digoxin monitoring can be affected: there is a clinical report of raised measured levels and laboratory evidence of assay cross-reactivity, with direction depending on assay. Anticoagulant, glucose-lowering and blood-pressure interactions are precautionary or uncertain. Immune-cell effects raise concern with immunosuppression. Caffeine and other stimulants may add insomnia, palpitations or anxiety.
Avoid or ask a doctor first if
Avoid unsupervised use during pregnancy/lactation, in children, with digoxin, uncontrolled hypertension or immunosuppressive treatment. Autoimmune and hormone-sensitive conditions warrant review. Stop and seek assessment for palpitations, marked blood-pressure changes or persistent insomnia.
Sources (PubMed, 12)
- Randomized controlled trial of Siberian ginseng for chronic fatigue.
PMID 14971626 · 2004 · Randomized controlled trialOverall null result in chronic fatigue, n=96, after two months; subgroup signal exploratory.
- No benefit adding eleutherococcus senticosus to stress management training in stress-related fatigue/weakness, impaired work or concentration, a randomized controlled study.
PMID 23740477 · 2013 · Randomized controlled trialNo added benefit with stress-management training in stress-related fatigue/weakness and impaired concentration.
- Assessment of the effects of eleutherococcus senticosus on endurance performance.
PMID 15902991 · 2005 · Narrative reviewReview of controlled endurance studies found no credible ergogenic benefit.
- Flow-cytometric studies with eleutherococcus senticosus extract as an immunomodulatory agent.
PMID 2963645 · 1987 · Randomized controlled trialSmall immune-cell study; counts are surrogate outcomes, not infection prevention.
- Effects of Siberian ginseng (Eleutherococcus senticosus maxim.) on elderly quality of life: a randomized clinical trial.
PMID 15207399 · 2004 · Randomized controlled trialOlder-adult quality-of-life signal at four weeks was not maintained at eight weeks.
- Combined Treatment with Two Water Extracts of Eleutherococcus senticosus Leaf and Rhizome of Drynaria fortunei Enhances Cognitive Function: A Placebo-Controlled, Randomized, Double-Blind Study in Healthy Adults.
PMID 31979283 · 2020 · Randomized controlled trialCognitive effects involved eleuthero leaf plus Drynaria, preventing single-ingredient attribution.
- Antiviral activity of an extract derived from roots of Eleutherococcus senticosus.
PMID 11397509 · 2001 · In vitro studyAntiviral activity was shown in cell culture, without human efficacy data.
- Simultaneous determination of Eleutheroside B and Eleutheroside E in rat plasma by high performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study.
PMID 23369882 · 2013 · Animal / preclinical studyRat plasma eleutheroside B/E pharmacokinetics; not human PK.
- Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng.
PMID 8705908 · 1996 · Case reportCase report of elevated measured digoxin with Siberian ginseng.
- Effect of Brazilian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab fragment of antidigoxin antibody (Digibind).
PMID 16040294 · 2005 · In vitro studyDigoxin immunoassay interference and cross-reactive ginseng components.
- Effect of Asian ginseng, Siberian ginseng, and Indian ayurvedic medicine Ashwagandha on serum digoxin measurement by Digoxin III, a new digoxin immunoassay.
PMID 18623124 · 2008 · In vitro studyDigoxin assay interference depends on analytical method.
- Effects of Acanthopanax senticosus HARMS extract on drug transport in human intestinal cell line Caco-2.
PMID 20091240 · 2010 · In vitro studyDrug transport effects in Caco-2 cells; human significance unknown.
Community comments
No approved comments yet. Comments are held for moderation.